a b c d e f g h i j k l m n o p q r s t u v w x y z #

Items starting with F Files

FEIBA (Factor VIII Inhibitor Bypassing Activity) Powder and solvent for solution for intravenous injection 500U F2S087AF

  • Date of Issuance: 1-Aug-18

FEIBA (Factor VIII Inhibitor Bypassing Activity) Powder and solvent for solution for intravenous injection 500U F2T053AB

  • Date of Issuance: 7-Nov-18

FEIBA (Factor VIII Inhibitor Bypassing Activity) Powder and solvent for solution for intravenous injection 500U F2T053AN

  • Date of Issuance: 16-Nov-18

FEIBA (Factor VIII Inhibitor Bypassing Activity) Powder and solvent for solution for intravenous injection 500U F2T053AN

  • Date of Issuance: 16-Nov-18

FEIBA (Factor VIII Inhibitor Bypassing Fraction) Powder for Injection 500 U VNF2S008

  • Date of Issuance: 20-Jun-17

FEIBA (Factor VIII Inhibitor Bypassing Fraction) Powder for Injection 500 U VNF2S030

  • Date of Issuance: 7-Nov-17

Flebogamma 5% DIF A4GBA00041

  • Date of Issuance: 03-Apr-17

Flebogamma 5% DIF A4GBA00061

  • Date of Issuance: 12-Apr-17

Flebogamma 5% DIF A4GBA00071

  • Date of Issuance: 09-Jun-17

Flebogamma 5% DIF A4GBB00011

  • Date of Issuance: 6-Oct-17

Flebogamma 5% DIF A4GBC00011

  • Date of Issuance: 23-Apr-18

Flebogamma 5% DIF A4GBC00031

  • Date of Issuance: 13-Jun-18

Flebogamma 5% DIF A4GBC00061

  • Date of Issuance: 4-Sep-18

Flebogamma 5% DIF A4GBC00071

  • Date of Issuance: 17-Jul-18

Flebogamma 5% DIF A4GBC00091

  • Date of Issuance: 17-Jul-18
[12  >>  

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Newsletter Subsription

Site Last Modified

  • Last Modified: Friday 22 March 2019, 15:10:03.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language